ImpediMed Inc.
5959 Cornerstone Court West
Suite 100
San Diego
California
92121
United States
Tel: 858-412-0200
Fax: 858-558-8540
Website: http://www.impedimed.com/
Email: info@impedimed.com
About ImpediMed Inc.
ImpediMed develops bioimpedance devices with a focus on medical applications in the fluid status area. Primary to this is the L-Dex U400 which measures extracellular fluid differences in the limbs for unilateral lymphedema.The company is pioneering the use of next generation bioimpedance technology in BIS (Bioimpedance Spectroscopy).
YEAR FOUNDED:
1999
LEADERSHIP:
Founder: Mel Bridges
CEO: Richard Carreon
JOBS:
Please click here for ImpediMed job opportunities.
PRODUCTS: All Products
FOLLOW IMPEDIMED:
Tweets byImpediMed
45 articles about ImpediMed Inc.
-
ImpediMed to Present Chronic Breast Cancer-related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting
4/11/2024
ImpediMed announced today that it will present new results from a breast cancer-related lymphedema study during a poster session at the American Society of Breast Surgeons (ASBrS) Annual Meeting in Orlando, FL on Friday, April 12, 2024.
-
Current Data Support Early Detection and Intervention to Reduce Rates of Breast Cancer-Related Lymphedema
10/26/2022
ImpediMed Limited is pleased to announce publication of a systematic literature review showing that early detection and intervention of breast cancer-related lymphedema reduces rates of chronic lymphedema in breast cancer patients.
-
ImpediMed Expands Use of SOZO in Leading Cancer Centers Focused on Reducing the Impact of Lymphedema after Breast Cancer
10/11/2022
ImpediMed Limited is pleased to announce the recent expansion of the use of its SOZO® Digital Health Platform at leading cancer centers dedicated to reducing the impact of lymphedema on breast cancer patients.
-
ImpediMed Announces U.S. Launch of Lymphedema Prevention Program with GenesisCare a Global Organization Dedicated to Care of Cancer Patients
10/4/2022
ImpediMed Limited is pleased to announce the signing of a Global Strategic Commercial Partnership and pilot program with GenesisCare.
-
ImpediMed Announces Two Posters at Heart Failure Society of America Annual Scientific Meeting That Demonstrate Utility of SOZO® Digital Health Platform for Heart Failure Patients
9/30/2022
ImpediMed Limited today announced two poster presentations at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, which is taking place Sept. 30 to Oct. 3 in Washington D.C.
-
72% of employers are currently experiencing a decrease in the volume of candidates applying to their jobs.
-
New Data Show Statistically Significant Reduction in Chronic Cancer-Related Lymphedema with Early Detection Using ImpediMed's L-Dex® Technology and Intervention
2/1/2022
ImpediMed Limited announced publication of results from the PREVENT trial showing that fewer breast cancer patients with early detection using L-Dex and intervention progressed to chronic lymphedema when compared to patients monitored with tape measure, which is the current standard of care.
-
ImpediMed Announces Next Generation of SOZO® Digital Health Platform Software
6/7/2021
ImpediMed Limited, a global medical technology company using bioimpedance spectroscopy to generate powerful data to improve patient health, announced the release of the next generation software for the SOZO® Digital Health Platform.
-
New Data Show ImpediMed's Lymphedema Prevention Program Reduces Incidence of Chronic Lymphedema in Breast Cancer Patients and Survivors
12/1/2020
ImpediMed Limited, a global medical technology company using bioimpedance spectroscopy to generate powerful data to improve patient health, announced the publication of a new study demonstrating that the company's Lymphedema Prevention Program reduces the incidence of chronic breast cancer-related lymphedema in breast cancer patients and survivors.
-
ImpediMed and The US Oncology Network Sign Agreement for Major Roll-Out of SOZO® Technology as Part of Lymphedema Prevention Program
6/29/2020
ImpediMed Limited, a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS), today announced a national purchasing a
-
NCCN Guidelines® for Breast Cancer Updated for Lymphedema
2/13/2020
Recommendations align with protocols outlined in ImpediMed's Lymphedema Prevention Program [13-February-2020] CARLSBAD, Calif. , and BRISBANE, Australia , Feb. 13, 2020 /PRNewswire/ -- ImpediMed Limited (ASX.IPD), a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscop
-
ImpediMed Receives FDA 510(k) Clearance of SOZO® for Expanded Indication
12/11/2019
ImpediMed Limited, a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy, recently announced the issuance of a further 510 clearance for SOZO® by the U.S. Food and Drug Administration.
-
US FDA 510(k) Clearance for Protein Calorie Malnutrition Assessment
11/27/2019
The claims around PCM are to aid clinicians who are using Subjective Global Assessment (SGA) tools to assess patients at risk of PCM.
-
ImpediMed Announces Ambitious New Program Aimed at Ending Cancer-Related Lymphedema
10/23/2019
ImpediMed Limited announces the kickoff of the company's new, comprehensive Lymphedema Prevention Program with the goal of ending cancer-related lymphedema.
-
ImpediMed’s Positive Interim Study Results Give Hope to Millions of Breast Cancer Survivors
5/16/2019
Professor Sheila Ridner, PhD, RN, FAAN, the Martha Rivers Ingram Professor of Nursing at Vanderbilt University School of Nursing, Principal Investigator, PREVENT trial.
-
PREVENT Interim Results – “Practice-Changing”
5/6/2019
Trial results on lymphoedema treatment using an Australian deviceshows strong improvement in patient outcomes
-
ImpediMed to Become Business Associate-Compliant with Launch of Third-Generation SOZO® Software
4/1/2019
ImpediMed will become Business Associate-compliant and launch third-generation software for its award-winning SOZO Digital Health Platform.
-
ImpediMed Announces PREVENT Trial Accepted for Publication and Presentation at the 2019 Annual Meeting of the American Society of Breast Surgeons
3/25/2019
Largest prospective, multi-center, randomized trial undertaken in the prevention of breast cancer-related lymphedema
-
Early Surveillance with L-Dex® Reduces Incidence, Severity & Cost of Breast Cancer-Related Lymphedema, ImpediMed Reports Publication in American Cancer Society Journal
12/12/2018
ImpediMed Limited today announced the publication of a landmark study from the prominent research institute Macquarie University.
-
ImpediMed Highlights Publication of Recommendations in New England Journal of Medicine: Supports Use of Bioimpedence and L-Dex Measurement for Lymphedema Assessment
12/4/2018
International authority on lymphedema, Stanley G. Rockson, M.D., calls for use of Bioimpedance Spectroscopy as protocol in surveillance and assessment of cancer survivors